Key statistics
On Friday, Danaher Corp (DHR:NYQ) closed at 270.03, -4.14% below its 52-week high of 281.70, set on Aug 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 271.56 |
---|---|
High | 272.56 |
Low | 268.65 |
Bid | 268.99 |
Offer | 270.48 |
Previous close | 270.52 |
Average volume | 1.78m |
---|---|
Shares outstanding | 722.21m |
Free float | 642.77m |
P/E (TTM) | 49.65 |
Market cap | 195.02bn USD |
EPS (TTM) | 5.44 USD |
Annual div (ADY) | 1.08 USD |
---|---|
Annual div yield (ADY) | 0.40% |
Div ex-date | Sep 27 2024 |
Div pay-date | Oct 25 2024 |
Data delayed at least 15 minutes, as of Oct 05 2024 00:00 BST.
More ▼
Press releases
- Danaher Schedules Third Quarter 2024 Earnings Conference Call
- Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership
- Danaher Announces Quarterly Dividend
- Danaher to Webcast Diagnostics Investor & Analyst Meeting in Washington, D.C.
- Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration
- Danaher Reports Second Quarter 2024 Results
- Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development
- Danaher Releases 2024 Sustainability Report
- Danaher Launches Beacon Research Collaboration with Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening
- Beckman Coulter Introduces New Integrated Chemistry and Immunoassay Analyzer
More ▼